OnKure Therapeutics assumed with a Buy at H.C. Wainwright

H.C. Wainwright assumed coverage of OnKure Therapeutics with a Buy rating and $40 price target following the completed a merger with Reneo Pharmaceuticals. The combined company is poised to advance OnKure’s pipeline candidates targeting oncogenic mutations in phosphoinositide 3-kinase alpha, the analyst tells investors in a research note.